Directly injectable formulations which provide enhanced cryoprotection of cell products
View Patent ↗This invention provides compositions and methods for cryoprotection of recombinant live cancer cells. Specifically, an improved cryoprotective medium is provided which includes a hydroxyethyl starch and/or derivative thereof alone or in combination with either DMSO or glycerol.
1. A method for preserving viability of proliferation-incompetent recombinant live cancer cells, the method comprising:
obtaining a plurality of recombinant live cancer cells;
concentrating the plurality of recombinant live cancer cells;
suspending said recombinant live cancer cells in a cryoprotective medium, wherein the cryoprotective medium comprises 5% by weight to about 22% by weight of a hydroxyethyl starch (HES) or derivative thereof and about 1% by weight to about 15% by weight of DMSO, thereby providing a suspension; and, freezing the suspension to a cryogenic frozen state, thereby providing a frozen suspension, wherein following thawing of the suspension to a liquid state at least about 60% of the suspended recombinant live cancer cells remain viable upon thawing.
2. The method of claim 1 , further comprising irradiating the recombinant live cancer cells wherein the recombinant live cancer cells are rendered proliferation-incompetent by irradiation.
3. The method of claim 2 , wherein the recombinant live cancer cells are rendered proliferation-incompetent by irradiation prior to freezing.
4. The method of claim 2 , wherein the recombinant live cancer cells are irradiated in the cryogenic frozen state.
5. The method of claim 1 , wherein the frozen suspension is frozen at − a temperature of from about −200° C. to a temperature of about −35° C.
6. The method of claim 1 , further comprising: thawing the frozen suspension thereby providing a thawed suspension and administering the thawed suspension to a subject, wherein the thawed suspension is not washed prior to the administering step.
7. The method of claim 1 , wherein the cryoprotective medium further comprises about 0% by weight to about 10% by weight human serum albumin (HSA).
8. The method of claim 7 , wherein the recombinant live cancer cells are mammalian cells selected from the group consisting of lung cancer cells, pancreatic cancer cells, prostate cancer cells, kidney cancer cells, myeloma cells, and leukemic cells.
9. A method of claim 8 , wherein the plurality of recombinant live cancer cells are autologous or allogeneic and further comprise an introduced heterologous nucleic acid coding sequence for granulocyte-macrophage colony stimulating factor (GM-CSF).
10. The method of claim 8 , wherein the recombinant live cancer cells are bystander cells, said method further comprising thawing the frozen suspension, thereby providing a thawed suspension; providing patient-derived tumor cells, mixing the thawed suspension with the patient-derived tumor cells, thereby providing a mixed suspension; and, administering the mixed suspension to a subject.
11. The method of claim 10 , wherein the patient-derived tumor cells comprise irradiated tumor cells.
12. The method of claim 7 , wherein the cryoprotective medium comprises about 8% by weight HES, about 2% by weight HSA, and about 5% by weight DMSO.
13. The method of claim 12 , further comprising: thawing the frozen suspension, thereby providing a thawed suspension; and, administering the thawed suspension to a subject wherein the thawed suspension is not washed prior to the administering step.
14. The method of claim 13 , wherein said recombinant live cancer cell is autologous.
15. The method of claim 13 , wherein said recombinant live cancer cell is allogeneic.
16. The method of claim 13 , wherein said recombinant live cancer cell is a bystander.